{"hands_on_practices": [{"introduction": "The bedrock of cost-effectiveness analysis involves comparing the additional cost of a new intervention, $\\Delta C$, to its additional health benefit, $\\Delta E$. This exercise guides you through the calculation of two fundamental metrics from first principles: the Incremental Cost-Effectiveness Ratio (ICER) and the Net Monetary Benefit (NMB). Mastering this practice [@problem_id:5003623] is the first step toward rigorously evaluating whether a new therapy offers good value for money within a health system.", "problem": "A biomarker-guided therapy is being evaluated against standard care in a translational medicine program. From a completed pragmatic trial and real-world implementation costing study, the incremental cost and incremental effectiveness of the biomarker-guided therapy relative to standard care are estimated as follows: incremental cost $\\Delta C = \\$12{,}000$, incremental effectiveness $\\Delta E = 0.4$ in Quality-Adjusted Life Years (QALYs). For health technology assessment, suppose the health system uses a societal willingness-to-pay threshold $\\lambda = \\$30{,}000$ per Quality-Adjusted Life Year.\n\nUsing only foundational definitions widely employed in health economics, proceed from first principles to:\n- derive the expression for the Incremental Cost-Effectiveness Ratio (ICER),\n- derive the expression for Net Monetary Benefit (NMB),\n- and formalize a decision indicator $D$ based on $NMB$ that encodes the adoption decision numerically, with the following convention: $D=1$ if the intervention is cost-effective at the threshold, $D=0$ if it is exactly indifferent at the threshold, and $D=-1$ if it is not cost-effective at the threshold.\n\nCompute the numerical values of the ICER, the NMB at $\\lambda$, and the decision indicator $D$. Express the ICER in dollars per Quality-Adjusted Life Year ($\\$/\\text{QALY}$) and the Net Monetary Benefit in dollars ($\\$)$. No rounding is required. Report your final result as a row matrix containing the three entries in the order $[\\text{ICER}, \\text{NMB}, D]$; do not include any units inside the matrix.", "solution": "The problem is subjected to validation.\n\n**Step 1: Extract Givens**\n- Incremental cost of the biomarker-guided therapy relative to standard care: $\\Delta C = \\$12{,}000$\n- Incremental effectiveness of the biomarker-guided therapy relative to standard care: $\\Delta E = 0.4$ Quality-Adjusted Life Years (QALYs)\n- Societal willingness-to-pay threshold: $\\lambda = \\$30{,}000$ per QALY\n- Task 1: Derive the expression for the Incremental Cost-Effectiveness Ratio (ICER).\n- Task 2: Derive the expression for Net Monetary Benefit (NMB).\n- Task 3: Formalize a decision indicator $D$ with the convention: $D=1$ for cost-effective, $D=0$ for indifferent, $D=-1$ for not cost-effective.\n- Task 4: Compute the numerical values of ICER, NMB, and $D$.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, as it uses fundamental and standard concepts of health economics and cost-effectiveness analysis, which are core to translational medicine and health technology assessment. The terms ICER, NMB, QALY, and willingness-to-pay threshold are well-defined and central to the field. The problem is well-posed, as all necessary data ($\\Delta C$, $\\Delta E$, $\\lambda$) are provided to compute the requested quantities. The language is objective and unambiguous. The numerical values are realistic for a new medical therapy. The problem does not violate any scientific principles, is not based on false premises, is not incomplete or contradictory, and is not ill-posed.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A complete, reasoned solution will be provided.\n\n**Solution Derivation**\n\nThe analysis proceeds from the foundational definitions of cost-effectiveness analysis. We are given the incremental cost, $\\Delta C$, and the incremental effectiveness, $\\Delta E$, of a new therapy compared to a standard of care.\n\n1.  **Incremental Cost-Effectiveness Ratio (ICER)**\n    The ICER is a primary metric in cost-effectiveness analysis. It represents the additional cost per unit of additional health outcome gained. By its fundamental definition, it is the ratio of the incremental cost to the incremental effectiveness.\n    \n    The expression for the ICER is:\n    $$\n    ICER = \\frac{\\Delta C}{\\Delta E}\n    $$\n    Using the provided numerical values:\n    $\\Delta C = 12000$ (in dollars)\n    $\\Delta E = 0.4$ (in QALYs)\n    \n    The numerical value of the ICER is calculated as:\n    $$\n    ICER = \\frac{12000}{0.4} = \\frac{120000}{4} = 30000\n    $$\n    The units of the ICER are dollars per QALY, or $\\$30,000/\\text{QALY}$.\n\n2.  **Net Monetary Benefit (NMB)**\n    The NMB is an alternative metric that quantifies the value of an intervention in monetary terms. It is derived by first monetizing the incremental health gain using the societal willingness-to-pay threshold, $\\lambda$, and then subtracting the incremental cost. The value $\\lambda \\cdot \\Delta E$ represents the monetary worth of the health gain, and $\\Delta C$ is its cost. The net benefit is the difference.\n    \n    The expression for the NMB is:\n    $$\n    NMB = (\\lambda \\cdot \\Delta E) - \\Delta C\n    $$\n    An intervention is considered cost-effective if its NMB is positive ($NMB > 0$), meaning the monetized value of the health gain exceeds the cost.\n    \n    Using the provided numerical values:\n    $\\lambda = 30000$ (in dollars per QALY)\n    $\\Delta E = 0.4$ (in QALYs)\n    $\\Delta C = 12000$ (in dollars)\n    \n    The numerical value of the NMB is calculated as:\n    $$\n    NMB = (30000 \\cdot 0.4) - 12000 = 12000 - 12000 = 0\n    $$\n    The unit of the NMB is dollars ($\\$$). An NMB of $0$ indicates that the monetized health gain is exactly equal to the cost of the intervention.\n\n3.  **Decision Indicator (D)**\n    The decision indicator $D$ is to be formalized based on the NMB and the specified decision rules. The intervention is:\n    - Cost-effective if $NMB > 0$.\n    - Indifferent if $NMB = 0$.\n    - Not cost-effective if $NMB  0$.\n    \n    The indicator $D$ is defined with the values $1$, $0$, and $-1$ corresponding to these three cases. This structure formally corresponds to the signum function, denoted $\\text{sgn}(x)$, which extracts the sign of a real number.\n    \n    Therefore, the decision indicator $D$ can be formalized as:\n    $$\n    D = \\text{sgn}(NMB) = \\text{sgn}((\\lambda \\cdot \\Delta E) - \\Delta C)\n    $$\n    where the signum function is defined as:\n    $$\n    \\text{sgn}(x) = \\begin{cases} 1  \\text{if } x > 0 \\\\ 0  \\text{if } x = 0 \\\\ -1  \\text{if } x  0 \\end{cases}\n    $$\n    We have already calculated that $NMB = 0$. Therefore, the value of the decision indicator is:\n    $$\n    D = \\text{sgn}(0) = 0\n    $$\n    A value of $D=0$ signifies that the therapy is exactly on the cusp of cost-effectiveness at the given willingness-to-pay threshold. This is consistent with the finding that the $ICER = \\$30,000/\\text{QALY}$, which is equal to the threshold $\\lambda = \\$30,000/\\text{QALY}$.\n\n**Summary of Computations**\n- ICER: $30000$ ($\\$/\\text{QALY}$)\n- NMB: $0$ ($\\$$)\n- Decision Indicator $D$: $0$\n\nThe final answer is to be presented as a row matrix $[\\text{ICER}, \\text{NMB}, D]$.", "answer": "$$\n\\boxed{\\begin{pmatrix} 30000  0  0 \\end{pmatrix}}\n$$", "id": "5003623"}, {"introduction": "While the ICER is a widely used metric, its interpretation can be misleading, particularly when it yields a negative value. This practice presents a hypothetical yet powerful scenario to demonstrate this ambiguity, where a highly desirable (dominant) intervention and a highly undesirable (dominated) one produce the same negative ICER. By deriving and applying the Net Monetary Benefit (NMB) framework, you will learn a more robust method that provides clear and unambiguous guidance for decision-making in all quadrants of the cost-effectiveness plane [@problem_id:4517472].", "problem": "A public health department is evaluating two mutually exclusive preventive interventions for reducing cardiovascular risk compared with usual care. Effects are measured in Quality-Adjusted Life Years (QALYs), and costs are measured in dollars. Let the incremental cost be $\\Delta C$ (new minus usual care) and the incremental effect be $\\Delta E$ (new minus usual care), and define the Incremental Cost-Effectiveness Ratio (ICER) as $\\mathrm{ICER} = \\frac{\\Delta C}{\\Delta E}$. The department uses a societal willingness-to-pay per QALY of $\\lambda$ dollars per QALY to value health gains.\n\nTwo candidate program designs yield the following incremental outcomes per participant:\n- Program A: $\\Delta C = -200$ and $\\Delta E = 0.01$.\n- Program B: $\\Delta C = 200$ and $\\Delta E = -0.01$.\n\nBoth programs yield an identical negative ICER when computed as a ratio, yet they represent opposing decision contexts in terms of desirability. Starting from the foundational definitions of incremental cost and effect, and the societal objective to maximize valued health, derive from first principles a single algebraic decision criterion in terms of $\\lambda$, $\\Delta E$, and $\\Delta C$ that avoids sign and magnitude ambiguity inherent in negative ICERs.\n\nThen, with $\\lambda = 50{,}000$ dollars per QALY, use your derived criterion to compute the incremental net monetary benefit for Program A and Program B. Finally, report the absolute difference between the two incremental net monetary benefits. Express the final value in dollars and round your answer to four significant figures.", "solution": "The problem is valid as it is scientifically grounded in the principles of health economics, is well-posed with all necessary information, and is expressed objectively.\n\nThe problem asks for the derivation of a decision criterion to evaluate health interventions that avoids the ambiguities associated with the Incremental Cost-Effectiveness Ratio (ICER), particularly when the ratio is negative. The ICER is defined as $\\mathrm{ICER} = \\frac{\\Delta C}{\\Delta E}$, where $\\Delta C$ is the incremental cost and $\\Delta E$ is the incremental effect. A negative ICER arises in two distinct scenarios:\n$1$. When $\\Delta C  0$ and $\\Delta E  0$: The new intervention is more costly and less effective (harmful). It is \"dominated\" by the comparator and should never be adopted.\n$2$. When $\\Delta C  0$ and $\\Delta E  0$: The new intervention is less costly (cost-saving) and more effective. It is \"dominant\" over the comparator and should always be adopted.\n\nThe provided data for Program A and Program B illustrate this ambiguity.\nFor Program A: $\\Delta C_A = -200$ and $\\Delta E_A = 0.01$. The ICER is $\\mathrm{ICER}_A = \\frac{-200}{0.01} = -20,000$. This program is dominant.\nFor Program B: $\\Delta C_B = 200$ and $\\Delta E_B = -0.01$. The ICER is $\\mathrm{ICER}_B = \\frac{200}{-0.01} = -20,000$. This program is dominated.\nThe identical negative ICER obfuscates the fact that Program A is highly desirable while Program B is highly undesirable.\n\nTo derive a universally applicable criterion from first principles, we start with the societal objective to maximize net health value. The societal willingness-to-pay, $\\lambda$, represents the monetary value society places on one unit of health effect (one QALY).\n\nThe value of the incremental health effect, $\\Delta E$, can be expressed in monetary terms by multiplying it by $\\lambda$. This gives the monetized value of the health gain: $\\lambda \\Delta E$.\n\nThe net benefit of an intervention is the difference between the value it produces and the cost it incurs. We define the Incremental Net Monetary Benefit (NMB) as the monetized value of the incremental health effect minus the incremental cost.\n\nThe algebraic expression for the NMB is:\n$$ \\mathrm{NMB} = (\\lambda \\times \\Delta E) - \\Delta C $$\n\nThis expression serves as the decision criterion. An intervention is considered cost-effective and desirable if its NMB is greater than zero:\n$$ \\mathrm{NMB}  0 \\implies \\lambda \\Delta E - \\Delta C  0 $$\nA positive NMB signifies that the monetary value of the health benefit surpasses the cost required to achieve it. This criterion is robust and resolves the ambiguity of the ICER because it does not involve division and its interpretation is independent of the signs of $\\Delta C$ and $\\Delta E$.\n\nNow, we apply this derived criterion to the two programs using the given willingness-to-pay threshold, $\\lambda = 50,000$ dollars per QALY.\n\nFor Program A:\nThe incremental cost is $\\Delta C_A = -200$ dollars.\nThe incremental effect is $\\Delta E_A = 0.01$ QALYs.\nThe incremental net monetary benefit for Program A is:\n$$ \\mathrm{NMB}_A = (\\lambda \\times \\Delta E_A) - \\Delta C_A = (50,000 \\times 0.01) - (-200) $$\n$$ \\mathrm{NMB}_A = 500 + 200 = 700 $$\nSince $\\mathrm{NMB}_A = 700  0$, Program A is deemed cost-effective, which is consistent with it being a dominant intervention.\n\nFor Program B:\nThe incremental cost is $\\Delta C_B = 200$ dollars.\nThe incremental effect is $\\Delta E_B = -0.01$ QALYs.\nThe incremental net monetary benefit for Program B is:\n$$ \\mathrm{NMB}_B = (\\lambda \\times \\Delta E_B) - \\Delta C_B = (50,000 \\times -0.01) - (200) $$\n$$ \\mathrm{NMB}_B = -500 - 200 = -700 $$\nSince $\\mathrm{NMB}_B = -700  0$, Program B is not cost-effective, which is consistent with it being a dominated intervention.\n\nFinally, the problem asks for the absolute difference between the two incremental net monetary benefits.\n$$ \\text{Absolute Difference} = |\\mathrm{NMB}_A - \\mathrm{NMB}_B| $$\n$$ \\text{Absolute Difference} = |700 - (-700)| = |700 + 700| = |1400| = 1400 $$\nThe resulting value is $1400$ dollars. The problem requires the answer to be rounded to four significant figures. The exact answer is $1400$. To unambiguously represent this with four significant figures, we write it in scientific notation as $1.400 \\times 10^3$.", "answer": "$$ \\boxed{1.400 \\times 10^3} $$", "id": "4517472"}, {"introduction": "Healthcare decisions often require choosing the best option from several alternatives, not just a simple comparison against the current standard of care. This exercise introduces the critical process of sequential analysis for multi-strategy comparison, a cornerstone of health technology assessment. You will learn to identify and eliminate inefficient options through the principles of strict and extended dominance, thereby constructing an \"efficiency frontier\" of the most viable strategies before making a final comparative assessment [@problem_id:5003695].", "problem": "A translational oncology program is evaluating three diagnosticâ€“treatment strategies for patients with advanced non-small cell lung cancer to guide targeted therapy initiation. Strategy $\\mathsf{A}$ is usual care (empiric therapy without molecular profiling). Strategy $\\mathsf{B}$ is a targeted Next-Generation Sequencing (NGS) panel with protocolized matched therapy. Strategy $\\mathsf{C}$ is a single-marker immunohistochemistry (IHC)-guided therapy approach. From a health system perspective over a $5$-year horizon, and using the outcome Quality-Adjusted Life Years (QALYs), the following incremental cost and effectiveness estimates are available relative to usual care $\\mathsf{A}$:\n- $\\mathsf{A}$: $\\Delta C_{\\mathsf{A}} = \\$0$, $\\Delta E_{\\mathsf{A}} = 0.00$ QALYs.\n- $\\mathsf{B}$: $\\Delta C_{\\mathsf{B}} = \\$7{,}300$, $\\Delta E_{\\mathsf{B}} = 0.10$ QALYs.\n- $\\mathsf{C}$: $\\Delta C_{\\mathsf{C}} = \\$8{,}000$, $\\Delta E_{\\mathsf{C}} = 0.05$ QALYs.\n\nUsing only the core definitions of dominance, extended dominance, and the incremental cost-effectiveness ratio (ICER), proceed as follows:\n1) Order strategies by increasing effectiveness $E$.\n2) Identify any strictly dominated strategy based on the fundamental definition that a strategy is strictly dominated if it is weakly more costly and weakly less effective than another, with at least one strict inequality.\n3) Test for extended dominance (also known as weak dominance by combination) by comparing incremental cost-effectiveness along the efficiency frontier constructed from strategies ordered by effectiveness, and use the principle that a strategy is extendedly dominated if its incremental cost-effectiveness ratio exceeds that of a more effective subsequent increment.\n4) After excluding any dominated and extendedly dominated strategies, compute the ICER of the remaining, more effective strategy versus the remaining, less effective strategy.\n\nExpress the final ICER in dollars per Quality-Adjusted Life Year (QALY) and round your answer to four significant figures.", "solution": "**Problem Validation**\n\n**Step 1: Extract Givens**\nThe problem provides three strategies, $\\mathsf{A}$, $\\mathsf{B}$, and $\\mathsf{C}$, with their incremental costs ($\\Delta C$) and incremental effectiveness ($\\Delta E$) relative to the baseline strategy, usual care ($\\mathsf{A}$).\n- Strategy $\\mathsf{A}$ (Usual Care): $\\Delta C_{\\mathsf{A}} = \\$0$, $\\Delta E_{\\mathsf{A}} = 0.00$ QALYs.\n- Strategy $\\mathsf{B}$ (NGS Panel): $\\Delta C_{\\mathsf{B}} = \\$7,300$, $\\Delta E_{\\mathsf{B}} = 0.10$ QALYs.\n- Strategy $\\mathsf{C}$ (IHC-guided): $\\Delta C_{\\mathsf{C}} = \\$8,000$, $\\Delta E_{\\mathsf{C}} = 0.05$ QALYs.\n\nThe outcome measure is Quality-Adjusted Life Years (QALYs).\nThe problem requires a stepwise analysis:\n1. Order strategies by effectiveness.\n2. Identify and remove any strictly dominated strategies.\n3. Identify and remove any extendedly dominated strategies.\n4. Calculate the Incremental Cost-Effectiveness Ratio (ICER) of the remaining non-dominated strategies.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded**: The problem is set in the context of translational oncology and health economics. Cost-effectiveness analysis, QALYs, ICER, dominance, and extended dominance are standard, validated concepts in this field. The values for costs and QALY gains are realistic for new diagnostic-treatment pathways in oncology. The problem is firmly based on established principles of health technology assessment.\n- **Well-Posed**: The problem is well-posed. It provides all necessary data and a clear, sequential set of instructions to arrive at a unique solution.\n- **Objective**: The problem is stated in objective, quantitative terms, free of bias or subjective claims.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A full solution will be provided.\n\n**Solution**\n\nThe analysis proceeds by following the four steps stipulated in the problem statement. We can tabulate the costs and effects of each strategy. Since strategy $\\mathsf{A}$ is the baseline, its incremental cost and effectiveness are zero.\n- Strategy $\\mathsf{A}$: Cost $C_{\\mathsf{A}} = \\$0$, Effectiveness $E_{\\mathsf{A}} = 0.00$ QALYs.\n- Strategy $\\mathsf{B}$: Cost $C_{\\mathsf{B}} = \\$7,300$, Effectiveness $E_{\\mathsf{B}} = 0.10$ QALYs.\n- Strategy $\\mathsf{C}$: Cost $C_{\\mathsf{C}} = \\$8,000$, Effectiveness $E_{\\mathsf{C}} = 0.05$ QALYs.\n\n**1) Order strategies by increasing effectiveness**\n\nWe arrange the strategies in ascending order of their effectiveness ($E$):\n- Strategy $\\mathsf{A}$: $E_{\\mathsf{A}} = 0.00$ QALYs\n- Strategy $\\mathsf{C}$: $E_{\\mathsf{C}} = 0.05$ QALYs\n- Strategy $\\mathsf{B}$: $E_{\\mathsf{B}} = 0.10$ QALYs\n\nThe ordered list of strategies is $\\mathsf{A}$, $\\mathsf{C}$, $\\mathsf{B}$. Their respective costs are $C_{\\mathsf{A}} = \\$0$, $C_{\\mathsf{C}} = \\$8,000$, and $C_{\\mathsf{B}} = \\$7,300$.\n\n**2) Identify any strictly dominated strategy**\n\nA strategy is strictly dominated if there exists another strategy that is both less costly and more effective. The definition states a strategy is strictly dominated if it is weakly more costly ($C_{dominated} \\geq C_{dominant}$) and weakly less effective ($E_{dominated} \\leq E_{dominant}$), with at least one inequality being strict. We compare pairs of strategies.\n- Compare $\\mathsf{A}$ and $\\mathsf{C}$: $C_{\\mathsf{C}}  C_{\\mathsf{A}}$ and $E_{\\mathsf{C}}  E_{\\mathsf{A}}$. Neither dominates the other.\n- Compare $\\mathsf{A}$ and $\\mathsf{B}$: $C_{\\mathsf{B}}  C_{\\mathsf{A}}$ and $E_{\\mathsf{B}}  E_{\\mathsf{A}}$. Neither dominates the other.\n- Compare $\\mathsf{C}$ and $\\mathsf{B}$: We have $C_{\\mathsf{C}} = \\$8,000$ and $E_{\\mathsf{C}} = 0.05$ QALYs for strategy $\\mathsf{C}$, and $C_{\\mathsf{B}} = \\$7,300$ and $E_{\\mathsf{B}} = 0.10$ QALYs for strategy $\\mathsf{B}$.\n\nWe check if strategy $\\mathsf{C}$ is dominated by strategy $\\mathsf{B}$.\n- Cost comparison: $C_{\\mathsf{C}} = \\$8,000  \\$7,300 = C_{\\mathsf{B}}$. Strategy $\\mathsf{C}$ is strictly more costly than $\\mathsf{B}$.\n- Effectiveness comparison: $E_{\\mathsf{C}} = 0.05  0.10 = E_{\\mathsf{B}}$. Strategy $\\mathsf{C}$ is strictly less effective than $\\mathsf{B}$.\n\nSince strategy $\\mathsf{C}$ is both more costly and less effective than strategy $\\mathsf{B}$, it is strictly dominated by $\\mathsf{B}$. A rational planner would never choose strategy $\\mathsf{C}$ when $\\mathsf{B}$ is available. Therefore, strategy $\\mathsf{C}$ is removed from further consideration.\n\nThe remaining strategies are $\\mathsf{A}$ and $\\mathsf{B}$.\n\n**3) Test for extended dominance**\n\nExtended dominance (or weak dominance by combination) occurs when a strategy's ICER, relative to the next less effective strategy on the efficiency frontier, is greater than the ICER of the next more effective strategy. This analysis requires at least three non-dominated strategies.\n\nThe remaining, non-dominated strategies, ordered by effectiveness, are:\n- Strategy $\\mathsf{A}$: $C_{\\mathsf{A}} = \\$0$, $E_{\\mathsf{A}} = 0.00$ QALYs.\n- Strategy $\\mathsf{B}$: $C_{\\mathsf{B}} = \\$7,300$, $E_{\\mathsf{B}} = 0.10$ QALYs.\n\nSince only two strategies remain, there is no intermediate strategy. The efficiency frontier consists of a single segment from $\\mathsf{A}$ to $\\mathsf{B}$. The concept of extended dominance is not applicable to eliminate any further strategies in this case. No strategy is extendedly dominated.\n\n**4) Compute the ICER of the remaining strategies**\n\nThe final step is to calculate the ICER for the most effective remaining strategy ($\\mathsf{B}$) compared to the next most effective strategy ($\\mathsf{A}$). The ICER is defined as the ratio of the incremental cost to the incremental effectiveness.\n$$\n\\text{ICER}(\\mathsf{B} \\text{ vs } \\mathsf{A}) = \\frac{C_{\\mathsf{B}} - C_{\\mathsf{A}}}{E_{\\mathsf{B}} - E_{\\mathsf{A}}}\n$$\nThe problem provides these incremental values directly, as all comparisons are relative to strategy $\\mathsf{A}$:\n$$\n\\Delta C = \\Delta C_{\\mathsf{B}} = C_{\\mathsf{B}} - C_{\\mathsf{A}} = \\$7,300\n$$\n$$\n\\Delta E = \\Delta E_{\\mathsf{B}} = E_{\\mathsf{B}} - E_{\\mathsf{A}} = 0.10 \\text{ QALYs}\n$$\nSubstituting these values into the ICER formula:\n$$\n\\text{ICER} = \\frac{\\$7,300}{0.10 \\text{ QALYs}} = \\$73,000 \\text{ per QALY}\n$$\nThe problem requires the answer to be rounded to four significant figures. The calculated value is exactly $73,000$. To express this unambiguously with four significant figures, we write it in scientific notation:\n$$\n73,000 = 7.300 \\times 10^4\n$$\nThis value represents the cost per QALY gained by choosing Strategy $\\mathsf{B}$ over Strategy $\\mathsf{A}$.", "answer": "$$\n\\boxed{7.300 \\times 10^4}\n$$", "id": "5003695"}]}